Article

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer

2025-06-03

Abstract excerpt

<h4>ABSTRACT</h4> Recent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatment is based on the premise that AR directly regulates expression of DNA repair genes, leading to synergy between PARP and AR inhibition. Despite some promisin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c6c7852-d13d-5c1a-b934-77f20af1aa8b
DOI: 10.1101/2025.06.02.657429

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerDOI 10.1101/2025.06.02.657429Read

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repairSemantic proximity Read

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.Semantic proximity Read

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read

CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP InhibitionSemantic proximity Read

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancerSemantic proximity Read

The interconnection between androgen receptor and DNA damage response pathways in prostate cancerSemantic proximity Read

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read